Business
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
With accelerated approval to treat the neurological and peripheral manifestations of Hunter syndrome, Denali’s Avlayah might be positioned as a rival to Takeda’s Elaprase.
CEO Rob Davis said the company is still interested in completing more deals after announcing the $5.7bn acquisition of Terns net of cash and mentioned immunology as an area of interest.
The gene-editing biotech is working on finalizing the protocol for Part C of the existing Phase I/II trial, and it will still need IRB approval and to train the sites on the new protocol.
Panellists at BIO-Europe Spring in Lisbon have welcomed the resurgence of interest in brain-related disorders
The Germany-based family-owned company, which has posted a decent set of financials for 2025 driven by Jardiance and Ofev, is particularly concerned about the red tape involved in getting clinical trials off the ground.
Its latest acquisition adds to Merck’s arsenal of hemato-oncology candidates, with TERN-701 aiming to challenge Novartis's Scemblix.
Lupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.
Leaders from Novartis, AstraZeneca, Eli Lilly and Novo Nordisk outlined how global capability centers in India are delivering tangible benefits across the value chain, from playing a key role at an awareness campaign during the US Super Bowl LX to sharply compressing study go-live timelines.
The acceleration of commercial health insurance was included in national development plans for 2026 released by the Chinese government in the recent “Two Sessions” policy meetings, and appears key for the next generation of innovative drugs to achieve domestic success.
Private Company Edition: Earendil executed two deals with Sanofi in 2025 around its artificial intelligence-based biologics discovery and development platform. Also, former Acorda CEO Ron Cohen emerges at Oryon Cell Therapies, which has raised $42m to date.
CEO Matt Gline talked to Scrip about preparing for the launch of brepocitinib in dermatomyositis, lessons learned from Vtama, and how smaller biopharmas are delivering launch successes.
The Phase III study’s principal investigator said that if Xpovio doesn’t win approval, NCCN Guidelines could enable off-label use, as has occurred with BMS’s Reblozyl.
Deal snapshot: Preparing for submission and potential approval and launch of its Phase III sleep apnea drug, Apnimed is divesting its half of Shionogi-Apnimed Sleep Science for $100m.
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
Restructuring Edition: Gossamer Bio, Bicycle Therapeutics and Evotec described plans to sharpen their focus and shrink their workforces. Also, Inovio, Vistagen and Amgen’s Horizon revealed job cuts, while BiomX and CNS Pharmaceuticals disclosed strategic shifts.
Activist investor and board chair Peter Tang takes on CEO role at Aurinia, while the COO, CMO and CFO also were replaced.
Pfizer, which licensed the candidate from Valneva, said the vaccine demonstrated clinically meaningful efficacy for preventing Lyme disease, even though the study failed to accrue enough cases.